Kathleen Gallagher

2.1k total citations · 1 hit paper
32 papers, 837 citations indexed

About

Kathleen Gallagher is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Kathleen Gallagher has authored 32 papers receiving a total of 837 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Genetics. Recurrent topics in Kathleen Gallagher's work include CAR-T cell therapy research (21 papers), Nanowire Synthesis and Applications (5 papers) and Immune Cell Function and Interaction (4 papers). Kathleen Gallagher is often cited by papers focused on CAR-T cell therapy research (21 papers), Nanowire Synthesis and Applications (5 papers) and Immune Cell Function and Interaction (4 papers). Kathleen Gallagher collaborates with scholars based in United States, United Kingdom and Germany. Kathleen Gallagher's co-authors include Marcela V. Maus, Matthew J. Frigault, Mark B. Leick, Bryan D. Choi, Christopher Mount, Sarah Nikiforow, William T. Curry, Leonora Balaj, Elizabeth R. Gerstner and Bob S. Carter and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Kathleen Gallagher

28 papers receiving 821 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma

2024 210 citations Bryan D. Choi, Elizabeth R. Gerstner et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kathleen Gallagher United States	12	633	212	196	195	151	32	837
Thomas J. Fountaine United States	10	596 0.9×	202 1.0×	240 1.2×	193 1.0×	149 1.0×	22	848
Sanfang Tu China	16	582 0.9×	144 0.7×	297 1.5×	201 1.0×	154 1.0×	52	858
Lori McIntyre United States	5	641 1.0×	220 1.0×	173 0.9×	194 1.0×	179 1.2×	8	700
Kai Rejeski Germany	19	753 1.2×	138 0.7×	279 1.4×	137 0.7×	160 1.1×	64	947
Brandon Ballard United States	10	847 1.3×	226 1.1×	326 1.7×	311 1.6×	259 1.7×	16	1.0k
Agne Taraseviciute United States	11	488 0.8×	163 0.8×	137 0.7×	94 0.5×	151 1.0×	15	647
Liqing Kang China	19	722 1.1×	246 1.2×	316 1.6×	188 1.0×	204 1.4×	68	944
Mireya Paulina Velasquez United States	15	589 0.9×	132 0.6×	218 1.1×	271 1.4×	156 1.0×	42	783
Corinne Summers United States	15	1.3k 2.1×	343 1.6×	319 1.6×	253 1.3×	411 2.7×	42	1.5k
Hannah Brakke United States	5	1.3k 2.1×	387 1.8×	343 1.8×	226 1.2×	393 2.6×	5	1.4k

Countries citing papers authored by Kathleen Gallagher

Since Specialization

Citations

This map shows the geographic impact of Kathleen Gallagher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathleen Gallagher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathleen Gallagher more than expected).

Fields of papers citing papers by Kathleen Gallagher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathleen Gallagher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathleen Gallagher. The network helps show where Kathleen Gallagher may publish in the future.

Co-authorship network of co-authors of Kathleen Gallagher

This figure shows the co-authorship network connecting the top 25 collaborators of Kathleen Gallagher. A scholar is included among the top collaborators of Kathleen Gallagher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathleen Gallagher. Kathleen Gallagher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gerstner, Elizabeth R., William T. Curry, Deborah Forst, et al.. (2025). Safety and tolerability of intraventricular CARv3-TEAM-E T cells following lymphodepleting chemotherapy in recurrent glioblastoma: INCIPIENT trial.. Journal of Clinical Oncology. 43(16_suppl). 2017–2017. 2 indexed citations

Moura, Lidia M.V.R., Rebecca G. Mishuris, Joshua P. Metlay, et al.. (2025). Hybrid Ambient Clinical Documentation and Physician Performance: Work Outside of Work, Documentation Delay, and Financial Productivity. Journal of General Internal Medicine.

Grauwet, Korneel, Trisha R. Berger, Michael C. Kann, et al.. (2024). Stealth transgenes enable CAR-T cells to evade host immune responses. Journal for ImmunoTherapy of Cancer. 12(5). e008417–e008417. 8 indexed citations

Lee, Won‐Ho, Charlotte Graham, Felix Korell, et al.. (2024). Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood. Cytometry Part B Clinical Cytometry. 106(3). 162–170.

DeFilipp, Zachariah, Haesook T. Kim, Guang‐Shing Cheng, et al.. (2024). A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT. Blood Advances. 9(2). 244–253. 3 indexed citations

Liu, Yiwen, Kathleen Gallagher, Emma Logan, et al.. (2024). Trial-in-Progress: A Phase 2 Study of Ruxolitinib in Low-Risk Essential Thrombocythemia and Polycythemia Vera Patients with High Symptom Burden. Blood. 144(Supplement 1). 6644–6644.

Atlas, Steven J., Kathleen Gallagher, Susan L. McGovern, et al.. (2024). Patient Perceptions on the Follow-Up of Abnormal Cancer Screening Test Results. Journal of General Internal Medicine. 40(6). 1280–1287. 1 indexed citations

Choi, Bryan D., Elizabeth R. Gerstner, Matthew J. Frigault, et al.. (2024). Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. New England Journal of Medicine. 390(14). 1290–1298. 210 indexed citations breakdown →

Graham, Charlotte, Won‐Ho Lee, Mark B. Leick, et al.. (2023). Chemotherapy-induced reversal of ciltacabtagene autoleucel–associated movement and neurocognitive toxicity. Blood. 142(14). 1248–1252. 32 indexed citations

10.

Larson, Rebecca C., Michael C. Kann, Charlotte Graham, et al.. (2023). Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma. Nature Communications. 14(1). 7509–7509. 23 indexed citations

11.

Gallagher, Kathleen, Mark B. Leick, Rebecca C. Larson, et al.. (2022). Differential T-Cell Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in mRNA-1273– and BNT162b2-Vaccinated Individuals. Clinical Infectious Diseases. 75(1). e869–e873. 6 indexed citations

12.

Leick, Mark B., Harrison Silva, Irene Scarfò, et al.. (2022). Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell. 40(5). 494–508.e5. 88 indexed citations

13.

Scarfò, Irene, Kathleen Gallagher, Mark B. Leick, et al.. (2021). Effects of Prior Exposure to Tec Kinase(BTK/ITK) Inhibitors on Kte-X19 Products. Blood. 138(Supplement 1). 3849–3849. 3 indexed citations

14.

Frigault, Matthew J., Yi‐Bin Chen, Kathleen Gallagher, et al.. (2021). Phase 1 Study of CD37-Directed CAR T Cells in Patients with Relapsed or Refractory CD37+ Hematologic Malignancies. Blood. 138(Supplement 1). 653–653. 11 indexed citations

15.

Larson, Rebecca C., Ana P. Castaño, Amanda A. Bouffard, et al.. (2020). Bispecific CAR T cells for multiple myeloma: natural ligand compared to tandem scFv design. The Journal of Immunology. 204(1_Supplement). 246.3–246.3. 3 indexed citations

16.

Frigault, Matthew J., Jörg Dietrich, María Martínez-Lage, et al.. (2019). Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 134(11). 860–866. 160 indexed citations

17.

Schmidts, Andrea, Maria Ormhøj, Bryan D. Choi, et al.. (2019). Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Advances. 3(21). 3248–3260. 85 indexed citations

18.

Milne, Paul, Charlotte S. Wilhelm-Benartzi, Michael R. Grunwald, et al.. (2019). Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. Blood Advances. 3(20). 3052–3061. 17 indexed citations

19.

Roberts, Gareth, Duncan M. Baird, Kathleen Gallagher, et al.. (2009). Functional Effector Memory T Cells Enrich the Peritoneal Cavity of Patients Treated with Peritoneal Dialysis. Journal of the American Society of Nephrology. 20(9). 1895–1900. 26 indexed citations

20.

Godkin, Andrew, Wan‐Fai Ng, Kathleen Gallagher, et al.. (2008). Expansion of hepatitis C–specific CD4+CD25+ regulatory T cells after viral clearance: A mechanism to limit collateral damage?. Journal of Allergy and Clinical Immunology. 121(5). 1277–1284.e3. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact